Press Releases

InVivo Therapeutics Reports Third Quarter 2013 Financial Results

Published: November 7, 2013

CAMBRIDGE, Mass. (November 7, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a life sciences company focused on the development and commercialization of novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions, today reported financial results for the three and nine months ended September 30, 2013. Michael Astrue, the interim CEO of InVivo, said, “We remain focused on our efforts to start our first clinical trial in the next quarter. We expect to provide investors with a clinical/regulatory update in the coming weeks as well as with an update […]

View Article
InVivo Therapeutics Appoints Lou Vaickus, MD as Interim Chief Medical Officer

Published: October 11, 2013

CAMBRIDGE, Mass. (October 11, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Lou Vaickus, MD has been appointed as interim Chief Medical Officer (CMO), effective October 15, 2013, for a period of one year. Currently, Dr. Vaickus is President of akta Pharmaceutical Development LLC. Prior to that, he served as Vice President and Head, Clinical Development, Global Medicines Development and Affairs at Vertex Pharmaceuticals. Before joining Vertex, Dr. Vaickus was CMO of Tolerx, Inc. from 2002 to 2011. […]

View Article
InVivo Therapeutics to Present at 2013 Aegis Healthcare Conference

Published: September 23, 2013

CAMBRIDGE, Mass. (September 23, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Brian Luque, Director of Investor Relations, is scheduled to present at the 2013 Aegis Healthcare Conference to be held September 25-28, 2013 at The Encore at Wynn Las Vegas. The Company’s presentation will be on Thursday, September 26th at 2:00 p.m. PDT. About the Neuro-Spinal Scaffold Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts […]

View Article
InVivo Therapeutics Appoints Gregory D. Perry as Interim CFO

Published: September 17, 2013

CAMBRIDGE, Mass. (September 17, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Gregory D. Perry has been appointed as interim CFO. Mr. Perry was most recently the Executive Vice President and CFO of Immunogen, Inc. Prior to joining Immunogen, Mr. Perry served as CFO of Elixir Pharmaceuticals, Inc. from 2007 to 2009. Prior to Elixir, he was CFO of Domantis Ltd., which was acquired by GlaxoSmithKline in 2006. Previously, Mr. Perry was Senior Vice President and CFO […]

View Article
InVivo Therapeutics Announces Personnel Changes

Published: September 9, 2013

CAMBRIDGE, Mass. (September 9, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that current Board member John A. McCarthy, Jr. has been appointed as non-executive Chairman of the Board. In addition, Board member Kenneth DiPietro has been appointed as a member of the Board’s Audit Committee. In addition, the acting CFO, Sean F. Moran, has resigned effectively immediately.  The Company is actively engaged in a search for a replacement.  In the meantime, the interim CEO, Michael J. Astrue, will serve […]

View Article
InVivo Therapeutics to Present at 15th Annual Rodman and Renshaw Healthcare Conference

Published: September 5, 2013

CAMBRIDGE, Mass. (September 5, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Acting Chief Financial Officer Sean Moran is scheduled to present to investors at the 15th Annual Rodman and Renshaw Healthcare Conference to be held September 8-10, 2013 at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Tuesday, September 10 at 2:25 pm ET in Room 704 on the 7th Floor. Additional information about the 15th Annual Rodman and Renshaw Healthcare Conference can be found at […]

View Article
InVivo Therapeutics Updates Clinical Plan

Published: August 27, 2013

CAMBRIDGE, Mass. (August 27, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced an update on the clinical timeline for its biopolymer scaffolding to treat acute SCI. The Company now expects that, based on the judgment of new management, it will enroll the first patient during the first quarter of 2014. Under the conditions of the FDA’s approval of the Investigational Device Exemption, the five-person pilot trial will be staggered such that each patient will be followed for three months prior to requesting […]

View Article
InVivo Therapeutics Announces Change in Leadership Francis M. Reynolds Resigns; Michael J. Astrue Appointed Interim CEO

Published: August 22, 2013

Boston, Mass., August 22, 2013 – The Board of Directors of InVivo Therapeutics Holdings Corp. (OTCBB: NVIV) today announced that Francis M. Reynolds has resigned from his positions as Chairman, CEO and CFO of the company due to his medical condition.  The Board has appointed Michael J. Astrue as interim CEO and Sean Moran, the company’s Director of Finance, as acting CFO, effective immediately. “We thank Frank Reynolds for his work in bringing InVivo to this point in its development,” said Ken DiPietro, InVivo Director and Chairman of the Board’s Governance, Nominating and Compensation Committee.  “We are fortunate that Michael […]

View Article
InVivo Therapeutics and the New York Mets Present Spinal Cord Injury Awareness Day

Published: July 10, 2013

CAMBRIDGE, Mass. (July 10, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company is teaming with the New York Mets to create Major League Baseball’s first Spinal Cord Injury Awareness Day on Sunday, September 15th at Citi Field when the New York Mets take on the Miami Marlins at 1:10 p.m. ET. InVivo has developed a treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while […]

View Article
InVivo Therapeutics Raises $16.1 Million From Warrant Call and Exercises Paving Way for Up-Listing to a National Securities Exchange

Published: June 4, 2013

CAMBRIDGE, Mass. (June 4, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, announced today that that the call notice period for the early exercise of warrants issued to investors on October 26, 2010, November 10, 2010 and December 3, 2010 (the “Investor Warrants”) expired on June 3, 2013. By the expiration of the call period, 100% of the Investor Warrants were exercised. The exercises during the call period, coupled with warrant exercises during April 2013, raised $16.1 million gross and $15.6 million after solicitation […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.